Currently submitted to: JMIR Research Protocols
Date Submitted: Mar 16, 2026
Open Peer Review Period: Mar 16, 2026 - May 11, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Oral versus intravenous fluid therapy in emergency department patients: protocol for a randomized controlled non-inferiority trial
ABSTRACT
Introduction: Intravenous fluid therapy is widely used in emergency departments (ED) to treat hypovolemia but is invasive and associated with potential complications. Oral fluid therapy represents a non-invasive alternative; however, evidence regarding its feasibility and its ability to achieve prescribed fluid volumes in ED patients is limited. This trial aims to evaluate the feasibility of oral fluid therapy and to determine whether it is non-inferior to intravenous fluid therapy in achieving prescribed fluid volumes. Methods and analysis: This investigator-initiated, multicenter, open-label, randomized controlled feasibility and non-inferiority trial will enroll 250 adult ED patients requiring fluid therapy. Participants are randomized 1:1 to receive oral fluid therapy or intravenous isotonic crystalloid. The primary feasibility outcome is protocol adherence. The primary clinical outcome is the proportion of patients achieving the prescribed fluid volume, analyzed using a non-inferiority method. Secondary outcomes include fluid volume received, length-of-stay, hospital free days, peripheral cannula use, acute kidney injury, severe electrolyte imbalance, blood pressure and feasibility measures. Analyses will follow the intention-to-treat principle. Recruitment began in 2025 and is ongoing. Ethics and dissemination: The study has received approval from the Danish ethics committee and data protection authorities. Results will be disseminated through peer-reviewed journals and scientific conferences.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.